2014 UALC
Camilla Christensen Ross, PhD
Dana-Farber Cancer Institute
Research Project:
Targeting Transcriptional Addictions in Small Cell Lung Cancer
Summary:
Previous work by Dr. Christensen and colleagues has suggested that amplified and overexpressed lineage-specific transcription factors govern SCLC biology and that downregulation of such factors could form the basis for SCLC targeted therapy. Based on a strong preclinical platform, Dr. Christensen aims to further explore the therapeutic potential of inhibitors that can modulate the general transcription apparatus and epigenetic state in SCLC. Further, she aims to investigate the malignant transcriptional circuits in SCLC biology to further guide drug discovery and therapeutic development for this malignant disease.